Our Portfolio


EMB-01 is a bispecific antibody based on EpimAb’s proprietary platform FIT-Ig® that has shown efficacy in multiple preclinical cancer models. It targets the Epidermal Growth Factor Receptor (EGFR) as well as the Hepatocyte Growth Factor Receptor (cMET). Currently, EMB-01 is in preclinical development, and scheduled for IND filing in China and the US during the course of 2018.

Further candidates:

EpimAb’s next candidates are well advanced and focused on the immuno-oncology area.